Copper & matrix remodeling
GHK-Cu in the skin
Skin has to preserve a barrier while rebuilding its supporting material. Copper-peptide research puts both jobs in the same frame.
Copper at the rebuilding site
GHK is glycine, histidine and lysine. GHK-Cu binds that tripeptide to a copper(II) ion in a 1:1 complex, also known as copper tripeptide-1. The copper is coordinated through histidine, the glycine amino group and a backbone amide nitrogen, leaving lysine’s side chain free. The sequence also appears within collagen type I, as well as SPARC/osteonectin.
In cell-culture (in vitro) findings from the skin-regeneration literature, GHK-Cu stimulates fibroblasts—the cells that make much of the skin’s supporting matrix—to produce collagen, elastin, glycosaminoglycans and decorin. In cell culture, it also regulates matrix-degrading enzymes and their inhibitors. Copper supports lysyl oxidase, which cross-links collagen and elastin. I’m fascinated by that continual exchange between construction and demolition: a remodeling tissue needs both.
Loren Pickart first isolated GHK from human plasma in 1973, following an effect on protein synthesis in aged liver tissue. The 2015 review describes plasma GHK falling from about 200 ng/mL at age 20 to about 80 ng/mL by age 60. That history explains some of the interest in aging; it supplies no proof that replacing GHK reverses aging.
The skin between the peptide and the target
A human skin penetration experiment measured copper delivery from GHK-Cu through excised, dermatomed skin. The permeability coefficient was 2.43 ± 0.51 × 10^-4 cm/h; over 48 hours, 136.2 ± 17.5 µg/cm² permeated and 97 ± 6.6 µg/cm² remained as a dermal depot. This was laboratory work with human skin, outside a living person.
The 2025 topical review identifies poor intact-skin permeability as a central difficulty. Free GHK’s clogP is -2.24; palmitoylation raises it to 1.14. The review also describes ~134 nmol GHK permeating after microneedle pretreatment versus none through intact skin in that experiment. These are delivery findings, with their own formulations and conditions. I’d hesitate to translate them into instructions for a bathroom shelf.
GHK-Cu creams and GHK gene data
The 2015 review of topical studies reports increased collagen production in 70% of treated women, compared with 50% for vitamin C and 40% for retinoic acid, along with small studies of firmness, fine lines and wrinkle depth. It is useful human evidence, anchored to topical formulations.
A 6-month hair-loss trial in 45 men tested a complex of 5-aminolevulinic acid and GHK. Hair-count increases were 52.6 at 100 mg/mL and 71.5 at 50 mg/mL, versus 9.6 with placebo (p<0.05), with no adverse events reported. The combination and the free GHK form matter here; assigning the entire effect to pure GHK-Cu would oversimplify the experiment.
The 2018 gene-expression analysis reports approximately 31.2% of human genes changing expression at a 50%-or-greater threshold, with roughly 59% upregulated and 41% downregulated. The table at that threshold covers roughly 2,100 genes; the familiar ~4,000 figure is an extrapolation. Those database signatures will impress me more if they survive protein-level and in-vivo testing. The largest headline number interests me less. Much of this foundational work and its review literature comes from Pickart and colleagues.
Formulation and safety questions
GHK-Cu has no FDA- or EMA-approved therapeutic indication. Topical copper tripeptide-1 is a legal cosmetic ingredient; injectable and systemic GHK-Cu lack drug approval and validated human pharmacokinetics. A licensed provider decides whether to prescribe the injectable form after an individual review.
The topical review discusses localized hyperpigmentation, including around 40% in one acne-scar microneedling study, and a small post-laser trial with no objective benefit despite greater satisfaction. Vitamin C/ascorbic acid and low-pH acids can destabilize the copper complex through formulation chemistry. Systemic copper accumulation remains a theoretical concern, especially with copper-handling disorders; published human copper-toxicity cases attributed to GHK-Cu have not been reported.
Community descriptions of firmer or smoother skin, irritation, breakouts and uneven pigmentation are anecdotal accounts, rather than clinical evidence. Injectable accounts carry still more uncertainty. To me, the topical human findings deserve their specific place, without being stretched into a whole-body repair claim. The comparison puts the forms and routes beside each other.